Medical device maker Medtronic, Inc. (MDT), Wednesday said it will expand its CURE-AF or Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation or AF clinical program with a post-market study into Europe and Canada. CURE-AF is being conducted in United States to secure Food and Drug Administration's approval for the drug Cardioblate for investigational treatment of AF patients.
Minneapolis, Minnesota-based Medtronic said the program will now collect post-market data internationally on the efficacy of irrigated cardiac ablation with radiofrequency -RF energy in AF patients.
In the CURE-AF investigation procedure, Medtronic's Cardioblate System will be used to create a pattern of transmural lesions, which span the full thickness of heart tissue that would be instrumental in restoring normal heart rhythm. The investigation procedure is an open heart surgery for the repair of valve or for coronary Artery Bypass Graft-CABG.
The company said Cardioblate surgical ablation system is currently indicated for cardiac tissue ablation, and has been used in more than 90,000 procedures worldwide.
MDT is currently trading at $33.99, down $0.08 or 0.26%, on a volume of 3.668 million shares.
For comments and feedback: editorial@rttnews.com